Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,042.63 -4.28 (-0.41%)
Streaming Delayed Price Updated: 11:27 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
40 41 Next >
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Growth Stocks You Need to Own Now for Maximum Returns
If you still want to stick around in the market for max returns, these growth stocks to buy should be intriguing for speculators. 
Via InvestorPlace
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
Why Regeneron Pharmaceuticals Stock Is Tanking Today
Investors are worried about Eylea's falling sales. 
Via The Motley Fool
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
Eylea sales fell and missed expectations in the U.S. 
Via Investor's Business Daily
AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Cathie Wood Stocks That Can Get You Through Any Recession
Shares of both companies moved higher even as the stock market fell last year. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 25
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For April 20
Via Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating  
Via Benzinga
Regeneron Reports First Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)  
Via Benzinga
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at... 
Via Benzinga
Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.